Data Release Review Committee (DRRC)
CO APCD Data Requests Summary
Meeting: October 6, 2021

22.36 CDPHE Cancer Case Identification and Enhancement Surveillance Project

Project Purpose:

The Colorado Central Cancer Registry (CCCR) is requesting identifiable data for patients who have received a cancer diagnosis in 2019 and 2020 in order to match these patients to those who have a reported case within the CCCR database. This project has three primary objectives:

1. To identify cancer cases that have gone unreported to the Colorado Central Cancer Registry (CCCR) (i.e., patients who have a cancer diagnosis who do not appear within the CCCR or existing patients who have been diagnosed with an additional form of cancer which is not reflected within the CCCR);
2. To enhance reported cancer cases with improved demographic data, especially patient race and ethnicity;
3. To assess the feasibility of using the APCD to improve CCCR data completeness and quality moving forward.

***CDPHE would do the matching in house as CCCR has very strict federal requirements around data sharing. CDPHE would be sending a list of codes to CIVHC for reportable cancers to pull cases from (and that would hopefully also catch people who have cases that aren't reported to CCCR yet). Please see the CODES reference in the supplemental application.*

Specific Aims:

(1) What percentage of CCCR cases were successfully matched to patients within the Colorado APCD?
(2) How many unreported cases of cancer were identified within the CO APCD?
(3) What percentage of CCCR cases with missing demographic data were able to be enhanced by CO APCD data?

Type of Data Requested:

Identifiable Data Set

CIVHC
CENTER FOR IMPROVING VALUE IN HEALTH CARE

22.34 Freenome Cancer Risk Research

Project Purpose:

Freenome is committed to broad patient access and to multiomics blood tests for the early detection of cancer. Freenome's multiomics platform detects key biological signals from a routine blood draw. The platform integrates assays for cell-free DNA, methylation, and proteins with advanced computational biology and machine learning techniques to understand additive signatures for early cancer detection.

This strategy incorporates a multidimensional view of both tumor- and non-tumor-derived (e.g. immune) signatures that enable the early detection of cancer, instead of relying only on tumor-derived markers, which may miss the early signs of cancer. By decoding cell-free biomarker patterns of once unthinkable complexity, Freenome's blood tests are powered by our multiomics platform and designed to detect cancer at its earliest stages to help clinicians optimize treatments and the next generation of precision therapies.

Although risk factors often influence the development of cancer, most do not directly cause cancer. Some people with several risk factors never develop cancer, while others with no known risk factors do. Knowing your risk factors and talking about them with your doctor may help you make more informed lifestyle and health care choices.

The purpose of this application is to request CO APCD Data for this research project to reinvent disease management through early detection and precision intervention and to equip all individuals and families with the tools they need to detect and treat cancer at its earliest and most manageable stages.

Specific Aims:

The project is to better understand risk factors that drive cancer and why it is happening in early stages. This research is being conducted to better understand predetermined risks around procedures within the cancer patient population above 40 years of age

1. What are the risk factors that drive cancer?
2. Why is cancer occurring in younger age group 40+?

Type of Data Requested:

Limited Data Set